A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis

Neurology

Volumn 50, Issue 6, 1998, Pages 1778-1783

  Palace, Jackie ^b   Newsom Davis, J ^c   Lecky, B ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PLACEBO; PREDNISOLONE; PYRIDOSTIGMINE;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MIXTURE; DYSPEPSIA; FEMALE; HUMAN; INSOMNIA; MALAISE; MALE; MULTICENTER STUDY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THYMOMA; VISUAL IMPAIRMENT;

EID: 0031747483     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1778     Document Type: Article

References (14)

1. Newsom-Davis J. Diseases of the neuromuscular junction. In: Asbury AK, McKhann GM, McDonald WI, eds. Diseases of the nervous system. Philadelphia: WB Saunders, 1992:197-212.
2. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252.
3. Delwaide PJ, Salmon J, Van Cauwenberge H. Premiers essais de traitement de la myasthénie par azathioprine. Acta Neurol Belg 1967;67:701-712.
4. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969;2:323-339.
5. Matell G, Bergström K, Franksson C, et al. Effects of some immunosuppressive procedures on myasthenia gravis. Ann NY Acad Sci 1976;274:659-676.
6. Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 1981; 377:691-698.
7. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984;15:602-605.
8. Cornelio F, Peluchetti D, Mantegazza R, Sghirlanzoni A, Collarile C. The course of myasthenia gravis in patients treated with corticosteroids, azathioprine, and plasmapheresis. Ann NY Acad Sci 1987;505:517-525.
9. Scherpbier HJ, Oosterhuis, HJ. Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis. Clin Neurol Neurosurg 1987;89:145-150.
10. Miano MA, Bosley TM, Heiman-Patterson TD, et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology 1991;41:919-921.
11. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242.
12. Myasthenia Gravis Clinical Study Group. A randomized clinical trail comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 1993;56:1157-1163.
13. Palace J, Newsom-Davis J, Lecky B, and the Myasthenia Study Group. A multicenter, randomized, double-blind trial of prednisolone plus azathioprine versus prednisolone plus placebo in myasthenia gravis. Neurology 1996;46:A332. Abstract.
14. Wiles CM, Karni Y. The measurement of muscle strength in patients with peripheral neuromuscular disorders. J Neurol Neurosurg Psychiatry 1983;46:1006-1013.